Bayer gains Betaferon approval in China

Published: 1-Dec-2009
Regulatory

The Chinese State Food and Drug Administration (SFDA) has approved Bayer Schering Pharma\'s Betaferon (interferon beta-1b) therapy for patients with relapsing-remitting multiple sclerosis (MS).


The Chinese State Food and Drug Administration (SFDA) has approved Bayer Schering Pharma's Betaferon (interferon beta-1b) therapy for patients with relapsing-remitting multiple sclerosis (MS).

Bayer plans to launch the drug in China by mid 2010. Betaferon is available in more than 100 countries around the world.

The approval is based on the results of Betaferon clinical trials, along with findings from a study designed to demonstrate the efficacy and safety of Betaferon among Chinese patients with relapsing-remitting MS. During the multi-centre six-month study, Betaferon significantly decreased the number of newly active lesions on MRI in Chinese patients, the company says.

Betaferon is marketed in the US and Canada as Betaseron.

Bayer says in the next five years it plans to invest Euro 100m in a centre for clinical research in Beijing. The company established a research and development centre in Beijing in February 2009.

  • Companies:
  • Bayer
See more

You may also like

Regulatory

Pistoia Alliance announces data management toolkit

Read more
Roche, AstraZeneca and Bayer supports FAIR Implementation project to improve data management and better AI and machine learning for the "Lab of the Future"

Trending Articles

  1. Overcoming CMC challenges in cell and gene therapy: part I Certara’s Dr Hien Anh Bruno, Associate Director, Chemistry, Manufacturing and Controls (CMC), and Dr Deven Shah, CMC Lead, propose mitigation strategies to address the CMC challenges inherent in producing cell and gene therapy (CGT) drugs
  2. The rising importance of preservative efficacy testing When considering the regulation and validation of pharmaceutical products, the efficacy of the active pharmaceutical ingredient (API) is often the main concern
  3. Tagrisso receives full approval in the EU For patients with locally-advanced or metastatic EGFR T790M mutation-positive non-small cell lung cancer
  4. AskBio receives FDA Fast Track Designation for congestive heart failure gene therapy programme The fast-tracking allows the development and expedition of review processes for AB-1002, a gene therapy to promote production of a constituently active form of I-1c
  5. Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for successful market entry from the early stages of development, reports Frederick Duynslaeger, Senior CMC Writer at Ardena

Upcoming event

Lounges

23-25 April 2024 | Conference | Messe Karlsruhe, Germany See all

You may also like

Regulatory

Pistoia Alliance announces data management toolkit

Roche, AstraZeneca and Bayer supports FAIR Implementation project to improve data management and better AI and machine learning for the "Lab of the Future"
Ingredients

Therapeutics: anticancer agent: larotrectinib

TRK (tropomyosin receptor kinase) fusion cancers occur when an NTRK gene fuses with another, unrelated gene, leading to the formation of an altered TRK protein
Ingredients

Therapeutics: darolutamide for prostate cancer

Prostate cancer is the second most commonly diagnosed cancer in men and leads to the fifth highest number of male cancer deaths
Media

Bayer receives European approval for haemophilia drug Jivi ... but has stiff competition ahead

Germany-based pharma major Bayer has recently received the European Commission approval for its haemophilia A long-acting injectable medicine Jivi
Regulatory

Australian beef and dairy industry welcomes registrations for tri-solfen

Patented pain relief product for animal husbandry procedures is marketed by Bayer in Australia
You need to be a subscriber to read this article.
Click here to find out more.
Regulatory

ADCs: a more effective, less harmful, targeted approach

Antibody-drug conjugates could hold the key to delivering highly potent anticancer drugs more accurately to the tumour site with less damage to healthy cells
You need to be a subscriber to read this article.
Click here to find out more.
Regulatory

US-India relations stall over pharma IP squabble

IP protection for international pharmaceutical companies in India remains an unresolved issue, as India battles for affordable medicines and the US argues that better patent protection must be forthcoming. The potential of this huge market hangs in the balance as discussions continue
Subscribe now